The U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa) for adults with metastatic castration-sensitive prostate cancer (mCSPC). This approval means darolutamide is now available as a treatment option for patients whose prostate cancer has spread but still responds to hormone therapy.
What Is Darolutamide?
Darolutamide is a medication that blocks the effects of male hormones (androgens) that can help prostate cancer grow. It was previously approved for use with the chemotherapy drug docetaxel in this setting.
How Was It Studied?
The approval is based on results from the randomized, double-blind, placebo-controlled phase 3 ARANOTE clinical trial, which included 669 men with mCSPC. Patients were randomly assigned to receive either darolutamide or a placebo, along with standard hormone therapy or after surgical removal of the testicles.
Key Results:
- Radiographic Progression-Free Survival (rPFS):
Patients taking darolutamide lived significantly longer without their cancer worsening on scans compared to those on placebo. The median time before cancer progression was not reached in the darolutamide group, while it was 25 months in the placebo group. This means patients on darolutamide had a lower risk of their cancer progressing during the study period (hazard ratio 0.54; p < 0.0001). - Overall Survival:
There was no statistically significant difference in overall survival between the groups at the time of final analysis (hazard ratio 0.78).
In a follow-up analysis, researchers looked at all patients who either started a new cancer treatment or passed away during the study. This included 45% of people who received darolutamide and 73% who received a placebo. Even after taking into account patients who began another treatment, those who received darolutamide still lived longer. On average, patients lived about 49 months with darolutamide compared to 32 months with placebo, which means the risk of death was reduced by more than half. These results confirm that adding darolutamide to hormone therapy and chemotherapy can help men with prostate cancer live longer, even if they later need additional treatment.
Side Effects and Safety:
The side effects seen with darolutamide in this study were similar to those reported previously. Important warnings include the risk of heart problems (ischemic heart disease), seizures, and potential harm to unborn babies if taken during pregnancy.
What This Means for Patients:
Darolutamide offers a new treatment option for men with metastatic castration-sensitive prostate cancer, helping to delay the progression of the disease. Patients should talk to their healthcare provider about whether darolutamide is right for them and discuss potential risks and benefits.
More Reading
Join the Conversation on CancerConnect!
Reference
